FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC
Written by
Cancer Network
Published
0
comments
0
min
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.